Medigus LTD. – American Depositary Share (NASDAQ:MDGS) Sellers Covered 33% of Their Shorts

May 10, 2018 - By Adrian Erickson

The stock of Medigus LTD. – American Depositary Share (NASDAQ:MDGS) registered a decrease of 33% in short interest. MDGS’s total short interest was 26,800 shares in May as published by FINRA. Its down 33% from 40,000 shares, reported previously. With 345,600 shares average volume, it will take short sellers 0 days to cover their MDGS’s short positions. The short interest to Medigus LTD. – American Depositary Share’s float is 1.16%.

The stock increased 1.69% or $0.02 during the last trading session, reaching $1.2. About 26,495 shares traded. Medigus Ltd. (NASDAQ:MDGS) has declined 82.68% since May 10, 2017 and is downtrending. It has underperformed by 94.23% the S&P500.

Medigus Ltd., a medical device company, develops, makes, and markets surgical endostaplers and direct vision systems for minimally invasive medical procedures in the United States, Europe, Asia, and internationally. The company has market cap of $4.66 million. It offers MUSE, an ultrasonic surgical endostapler system for the treatment of gastroesophageal reflux disease; and miniaturized video cameras for use in various medical procedures, as well as specialized industrial applications. It currently has negative earnings.

More recent Medigus Ltd. (NASDAQ:MDGS) news were published by: Globenewswire.com which released: “Medigus and HC Marbella International Hospital Announce First MUSEâ„¢ Procedure for GERD Treatment in Spain” on April 17, 2018. Also Investingnews.com published the news titled: “Medigus and HC Marbella International Hospital Announce First MUSE Procedure for GERD Treatment in Spain” on April 18, 2018. Investingnews.com‘s news article titled: “Medigus and HC Marbella International Hospital Announce Successful First Procedure in Spain” with publication date: April 18, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.